CTLA4 and metastatic melanoma: To explore whether the IIS risk score could predict immunotherapy response, we applied the IIS risk score to the Van_allen dataset, the sequencing data from metastatic melanoma treatment with cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) blockade (ipilimumab).